.png)
Executive Summary
The Indian Chemical industry forms the backbone of industrial and agricultural development of the nation. Over the years, the industry has evolved from a basic chemical producer to an innovative industry, registering significant growth in the knowledge sector comprising pharmaceuticals, biotechnology and agrochemicals. However, to strengthen industrial growth, innovation and competitive performance of this sector and to position the industry on the global map, extensive technology inputs are required to make the industry capable of producing world class end products. In recent years, efforts have been made to study the Knowledge Chemical industry from the perspective of growth and global competitiveness, however, studies on identifying and addressing the technology gaps so as to formulate a technology roadmap with short term and long term perspectives are limited. Considering the importance of this sector, TIFAC, jointly with the Indian Chemical Council (ICC), Mumbai has commissioned a specialised study on ‗Indian Knowledge Chemical industry – Technology Imperatives and Business Opportunities‘. TIFAC has engaged the services of ICRA Management Consulting Services Ltd. (IMaCS) to conduct the aforesaid study. The study encompasses the pharmaceuticals, biotechnology and agrochemical sectors.
The report gives good coverage on the business opportunities, global technology trends and total market size of pharmaceutical, industrial biotechnology & agrochemical industry in India. IMaCS has also reported on the emerging global trends that offer significant business opportunities for Indian industry. This includes the area of generic drugs, expiration of patents on key ‘blockbuster’ drugs to enable India produce off-patent drugs, novel drug delivery systems (NDDS), biopharmaceutical therapeutics, herbal medicines based on products available in India etc. As a part of the study, IMaCS also analyzed the R&D capabilities of the Indian industry vis-a-vis the other countries on various parameters including R&D expenditure of Indian companies, major areas of research, infrastructure available for R&D, technologies used and human resource related aspects. The key gaps in R&D includes low investment on R&D, limited success in new drug discovery, limited efforts in NDDS, significant lag in the technologies used in biopharmaceuticals, lack of efficient usage of available technologies, limited use of bioinformatics, limited focus on drug design, limited accessibility to biological testing facilities, lack of adequate infrastructure for non-human primate testing etc.
Price Rs. 30,000
